Left Atrial Appendage Occlusion vs. Usual Care in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease

Atrial Fibrillation Clinical Trial

— WatchAFIB  

Official title:

WATCH Bleeding Episodes After Left Atrial Appendage Occlusion Versus Usual Care in Patients With Atrial FIBrillatIon and Severe to eNd-stage Chronic Kidney Disease (WatchAFIB in CKD)

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02039167
• Other study ID #: OVGU-014-Kar
• Status: Terminated
• Phase: N/A
• Start date: January 2014
• Est. completion date: April 12, 2017

Study information

• Verified date: November 2018
• Source: University of Magdeburg
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the superiority of left atrial appendage occlusion in comparison to oral anticoagulation with a vitamin K antagonist (INR 2-3) related to the frequency of occurrence of at least one bleeding classified as moderate or major within 24 months.

Description:

Open, randomized, controlled, multicenter clinical investigation. Transesophageal echocardiography (TEE) for all patients within 14 days of the Enrolment Visit. Patients randomized to oral anticoagulation (OAC) will receive standard of care (SOC) vitamin K antagonist treatment throughout the 24 months clinical investigation period, managed by the primary care physician, with the goal of achieving and maintaining an INR of 2-3 (INR monitoring by the primary care physician every two weeks throughout study period).

Patients randomized to the WATCHMAN device will undergo device implantation within 48 hours of the screening TEE and after confirmation of INR ≤ 1.7 in the catheterization laboratory with a subsequent hospitalization for 24-48 hours.

Concomitant treatment with Aspirin/Clopidogrel (managed by the patient's primary care physician) will be initiated on the day prior to device implantation, and will be continued for 6 months after the procedure, at which time Clopidogrel will be discontinued; administration of Aspirin will be continued indefinitely.

Follow-up visits for all patients will take place on Day 45, and at Month 6, Month 12 and Month 24 (End of Study). Routine safety and efficacy assessments at each visit will be the same for all patients regardless of treatment group.

Follow-up- visits at day 45, months 6, 12 and 24. Patients randomized to the WATCHMAN device will have additional TEE imaging performed at the Day 45 and Month 6 visits.

An independent Data Monitoring Committee will monitor safety. A blinded and independent Endpoint Committee will evaluate end-points throughout the entire study period.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 14
• Est. completion date: April 12, 2017
• Est. primary completion date: March 21, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Paroxysmal, persistent, or permanent non-valvular atrial fibrillation (AF), documented by electrocardiography performed at screening or within the prior 6 months

• Indication for oral anticoagulation as assessed by CHA2DS2-VASc-Score (= 2)

• Severe to end-stage chronic kidney disease (eGFR < 30 ml/min as determined by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula)

• 18 to 80 years, inclusive

• Life expectancy of at least 2 years

• Negative pregnancy test for women

• Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent

• Written informed consent

Exclusion Criteria:

• AF due to a reversible cause or a singular occurrence of AF

• Conditions other than AF that require anticoagulation

• Transient ischemic attack or stroke within previous 3 months

• A need for Aspirin (at a dose of > 162.5 mg/day) or for both Aspirin and Clopidogrel/other antiplatelet drugs (daily administration) other than for clinical investigation

• Contraindications or allergies to vitamin K antagonists, Aspirin or Clopidogrel

• Previous closure (surgical, interventional) of the left atrial appendage (LAA)

• Previous closure of atrial septal defect (ASD) / persistent foramen ovale (PFO)

• Active internal bleeding

• Thrombocytopenia (< 100,000 platelets/mm3)

• History of or planned organ transplantation

• Planned Mitra Clip or transcatheter aortic valve implantation (TAVI) intervention

• Planned cardiac surgery

• History of intracranial, intraocular or retroperitoneal bleeding

• Severe GI-bleeding within the last 3 months

• Hemorrhagic gastro-intestinal diseases (e.g., ulcerative colitis)

• History of or condition associated with increased bleeding risk

• Uncontrolled arterial hypertension

• Heparin-induced thrombocytopenia type II

• Known inherited coagulation disorders

• Severe liver dysfunction (spontaneous INR > 1.5) or liver cirrhosis = CHILD B

• Chronic use of non-steroidal anti-inflammatory drugs (NSAIDs)

• Women who are planning to become pregnant, or who are breastfeeding

• Active infection of any kind

Transesophageal echocardiography (TEE) Exclusion Criteria

• Intracardiac thrombus or dense spontaneous echo contrast as visualized by TEE (with use of sonovue in suspicious cases)

• Significant mitral valve stenosis

• Any congenital heart disease, including atrial septal defect

• Pericardial effusion during ECHO assessment of > 2 mm

• Cardiac tumor

Related Conditions & MeSH terms

• Atrial Fibrillation
• Blood Coagulation Disorders
• Chronic Kidney Disease Stage 4
• Chronic Kidney Disease Stage 5
• Hemostatic Disorders
• Kidney Diseases
• Kidney Failure, Chronic
• Renal Insufficiency, Chronic
• Thrombosis
• Thrombosis of Left Atrial Appendage

Intervention

Device:
• Left atrial appendage occlusion
Percutaneous left atrial appendage closure using the WATCHMAN device.

Locations

Country	Name	City	State
Germany	Zentralklinik Bad Berka - Klinik für Kardiologie	Bad Berka
Germany	CCB im Markus Krankenhaus Frankfurt	Frankfurt
Germany	Medizinische Hochschule Hannover Zentrum Innere Medizin, Abt. Kardiologie und Angiologie	Hannover
Germany	Otto-von-Guericke University Magdeburg, Faculty of Medicine	Magdeburg	Saxony-Anhalt

Sponsors (1)

Lead Sponsor	Collaborator
University of Magdeburg

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Time to occurrence of first moderate and major bleeding as well as to occurrence of stroke (ischemic or hemorrhagic) according to the modified Rankin scale		24 months
Primary	Frequency of occurrence of moderate and major bleedings (Type 2 to Type 5 according to the Bleeding Academic Research Consortium (BARC) definitions)		24 months
Secondary	Frequency of at least one occurrence of a combined endpoint of moderate or major bleeding and/or severe cardiovascular adverse events (stroke, cardiac infarction, thrombosis, death)		24 months